Background/Aims: An increasing number of studies have linked erythropoietin-producing hepatocellular carcinoma (Eph) family receptor tyrosine kinases to cancer progression. However, little knowledge is available about the regulation of their functions in cancer. Methods: SUMOylation was analyzed by performing Ni 2+ -NTA pull-down assay and immunoprecipitation. Cell proliferation, anchorage-independent growth, and tumorigenesis in vivo were examined by cell counting kit-8, soft agar colony formation assay, and a xenograft tumor mouse model, respectively. Results: We found that EphB1 was post-translationally modified by the small ubiquitin-like modifier (SUMO) protein at lysine residue 785. Analysis of wild-type EphB1 and SUMOylation-deficient EphB1 K785R mutant revealed that SUMOylation of EphB1 suppressed cell proliferation, anchorage-independent cell growth, and xenograft tumor growth. Mechanistic study showed that SUMOylation of EphB1 repressed activation of its downstream signaling molecule PKCγ, and consequently inhibited tumorigenesis. A reciprocal regulatory loop between PKCγ and SUMOylation of EphB1 was also characterized. Conclusion: Our findings identify SUMO1 as a novel key regulator of EphB1-mediated tumorigenesis.
Sumoylation of EphB1 Suppresses Neuroblastoma Tumorigenesis via Inhibiting PKCγ Activation
they act as both tumor promoters and suppressors depending on cancer type and cellular context [1] [2] [3] . EphB1 is overexpressed in migrating medulloblastoma cells and contributes to medulloblastoma cell migration, growth, and radiosensitization [4, 5] . Conversely, in renal cell carcinomas, glioma, and ovarian, gastric, and colorectal cancers, EphB1 expression is downregulated [6] [7] [8] [9] . EphB1 plays a tumor suppressor role in acute myelogenous leukemia (AML) by regulating DNA damage response [10] . However, the role of EphB1 in neuroblastoma has not been clarified. Neuroblastoma is a common biologically and clinically heterogeneous pediatric tumor of neural crest origin. These reported paradoxical functions of EphB1 make it of interest to investigate the role of EphB1 in neuroblastoma.
Despite accumulating evidence linking EphB1 to cancer, little is known about the regulation of EphB1 by post-translational modification. So far, phosphorylation and ubiquitination have been reported to be involved in post-translational modulation of EphB1 activity. Ligand binding induces EphB1 oligomerization and subsequent phosphorylation at specific tyrosine residues in the cytoplasmic domain, which interacts with a number of cytoplasmic signaling molecules such as Grb2, Nck, and Src [11] [12] [13] . Following ligand stimulation, EphB1 is ubiquitinated by the E3 ubiquitin ligase Cbl and is subsequently degraded through the lysosomal pathway [14] .
SUMOylation is an enzymatic cascade reaction that involves covalent and reversible conjugation of small ubiquitin-like modifiers (SUMO) to specific lysine residues in protein substrates. This form of post-translational modification regulates protein activity, subcellular localization, and stability [15] . Several studies show that SUMOylation can target various proteins including nuclear and cytoplasmic proteins, but little is known about SUMOylation of transmembrane proteins [16] [17] [18] [19] .
Here, we show that receptor tyrosine kinase EphB1 is modified by SUMO1 at lysine residue K785. EphB1 SUMOylation then suppresses activation of PKCγ, and thus inhibits tumorigenesis. This study therefore uncovers a novel regulatory mechanism by which the function of EphB1 in tumorigenesis is specifically modulated.
Materials and Methods

Antibodies and reagents
Antibodies against Flag M2 (#F1804), HA (#H3663), and His-tag (#SAB2702218) were purchased from Sigma-Aldrich (St. Louis, MO). Anti-SUMO1 (#ab32058) and anti-SENP1 (#ab108981) antibodies were from Abcam Inc. (Cambridge, MA). Antibodies against EphB1 (#sc-926), PKCγ (#sc-211) and normal mouse IgG (#sc-2025) were from Santa Cruz Biotechnology (Santa Cruz, CA). Phosphor-PKCγ antibody (#9379) was purchased from Cell Signaling Technologies Inc., (Danvers, MA). Ni 2+ -NTA agarose beads were obtained from Qiagen (Valencia, CA). Protein G plus / Protein A agarose suspension (#IP05) was from Calbiochem (San Diego, CA). Puromycin (#P8833) and polybrene (#H9268) were from Sigma-Aldrich (St. Louis, MO).
Cell culture
Human neuroblastoma SH-SY5Y cells were purchased from ATCC (Manassas, VA) and cultured in RPMI 1640 containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. NG108, Neuro-2a, HEK293T, and 293FT cells were cultured in DMEM containing 10% FBS, 100 U/mL penicillin, and 100 mg/ mL streptomycin. All the cells were grown at 37 °C in a humidified incubator under 5% CO 2 .
Plasmids construction and transfection
The pcDNA3.1-EphB1 plasmid was kindly provided by Dr Nanjie Xu. HA-EphB1 cDNA was subcloned into the lentiviral vector (System Biosciences LLC, Palo Alto, CA) carrying puromycin and EGFP genes. The shRNAs were subcloned into pLKO.1 vector. PKCγ shRNA CCGGGCCTCCACTCTAGTTCTAGATCTCGAGATCTAGAACTAGAGTGGAGGCTTTTTTG; SENP1 shRNA#1 CCGGTGGGAACATTCAGTACATGACTCGAGTCATGTACTGAATGTTCCCTTTTTG; SENP1 shRNA #2 CCGGTAGAATACTCTTGCAATACCCTCGAGGGTATTGCAAGAGTATTCTT TTTTG.
The above plasmids were co-transfected with the packaging plasmids into 293FT cells using -NTA resin as previously described [20] , followed by immunoblotting with antibody against HA. As loading control, the whole cell lysate before Ni 2+ -NTA pull-down was stained for HA, β-actin, Ubc9, and GFP.
Immunoprecipitation HEK293T cells were co-transfected with HA-EphB1, His-SUMO1, and Flag-Ubc9 for 48 hr. After washing with NEM-PBS buffer (20 mM N-ethylmaleimide in PBS), cells were lysed in NEM-RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 20 mM N-ethylmaleimide, and complete protease inhibitor cocktail). Then, 1 mg of the cell lysates was immunoprecipitated with anti-HA antibody and then immunoblotted with anti-His antibody.
Quantitative realtime PCR (qRT-PCR)
qRT-PCR was performed as described before [21] . Briefly, total RNA was extracted from three neuroblastoma cell lines and reverse transcribed. Real-time PCR was performed and EphB1 expression was normalized to that of GAPDH. Primers for qRT-PCR are listed as follows. EphB1 forward primer: GATGAAGATCTACATTGACCC; reverse primer: TAGATTTCCCTCTTGCCTGG. GAPDH forward primer: GATGACATCAAGAAGGTGG; reverse primer: ATGAGGTCCACCACCCTGTT.
Western blot
Cells were lysed in SDS lysis buffer (62.5 mM Tris pH 6.8, 1% SDS) and the protein concentration of the cell lysates determined by NanoDrop Spectrophotometer. Equal amounts of protein were loaded onto SDS-PAGE gel and transferred to nitrocellulose membranes. Western blot was performed using primary antibodies and secondary antibodies conjugated with HRP. Protein bands were visualized by enhanced chemiluminescence (ECL kit, Pierce Biotechnology, Rockford, IL).
Soft agar colony formation assay
Anchorage-independent growth of tumor cell lines was assessed by soft agar colony assays. Briefly, 1 × 10 3 cells were suspended in 2 mL of 0.35% agar gel with 2% FBS and then seeded in 6-well plates with a base of 2 mL of 0.6% agar gel containing 2% FBS. After incubation at 37 °C for two weeks, photographs of the colonies were taken after crystal violet staining and the number of colonies was counted.
Mouse xenograft model SH-SY5Y cells expressing empty vector, wild-type EphB1, or EphB1 K785R mutant (2 × 10 6 ) were suspended in 100 μL of serum-free medium and subcutaneously injected into 6-week-old male nude mice. Tumor growth was measured every 4 days and tumor volume was calculated as 1/2 × length × width 2 . Tumors were harvested 3 weeks after injection, and then photographed and weighed. All animal studies were conducted with the approval and guidance of Shanghai JiaoTong University Medical Animal Ethics Committee. 
Statistical Analysis
Results
EphB1 is modified by SUMO1
To determine if EphB1 undergoes SUMOylation, HEK293T cells were co-transfected with HAtagged EphB1 (HA-EphB1), the SUMO conjugating enzyme Ubc9, and His6-tagged SUMO1 (His-SUMO1). SUMOylated proteins were enriched by Ni 2+ -NTA pull-down assays, followed by immunoblotting with anti-HA antibody. HA-EphB1 was detected as a single band of the expected 120 kDa molecular weight. When cells were transfected with HA-EphB1, His-SUMO1, and Ubc9, we observed two strong higher molecular weight bands of around 135 and 150 kDa (Fig. 1A) , which corresponded to mono-and diSUMOylated EphB1. The intensity of these two bands was reduced after co-transfection of SUMO1-specific protease SENP1 (Fig. 1B) . To further confirm that the shift resulted from SUMOylation, we stably knocked down SENP1 in HEK293T cells by using SENP1 shRNA #1 or #2. Then EphB1, Ubc9, and SUMO1 were co-transfected and Ni
2+
-NTA pulldown assays were performed. As shown in Fig. 1C , SUMOylated EphB1 protein increased after SENP1 was down-regulated, which was further validated by immunoprecipitation assay (Fig. 1D ).
K785 is a major site for SUMOylation
SUMOs are conjugated to the lysine residues of target proteins often found within the consensus sequence ψKX(D/E), where ψ is a hydrophobic amino acid and X is any amino acid. Seven potential SUMOylation sites of EphB1 were predicted by SUMOplot (www. abgent.com/sumoplot) ( Fig. 2A) . We then mutated these lysine residues to arginine residues individually in HA-EphB1 and examined whether these mutants could be SUMOylated. The results from Ni 2+ -NTA pull-down assays showed that SUMOylation of EphB1 was strongly reduced by mutation of K785 to arginine (Fig. 2B) . Although mutation of K643 to arginine also had a slight effect on EphB1 SUMOylation, the level of SUMOylation was comparable between single mutation K785R and double mutation K643/785R (Fig. 2C) , indicating that K785 is the major site for SUMOylation.
To confirm the results of Ni
2+
-NTA pull-down assay, we also examined the SUMOylation of EphB1 with K785R mutation by immunoprecipitation assay. HEK293T cells were transfected with HA-EphB1 or the K785R mutant, His-SUMO1, and Ubc9. Cell lysates were immunoprecipitated with anti-HA antibody and immunoblotted with anti-His antibody. Consistently, mutation of K785 to arginine reduced the SUMOylation of EphB1 (Fig. 2D) . 
The motif containing K785 is located in the kinase domain and remains highly conserved in vertebrates (Fig. 2E) . Using the crystal structure depicting the tyrosine kinase domain of EphB1 [22] (amino acids 602 -896, taken from Protein Data Bank [PDB]: 3ZFX_A), we found that the major site for SUMO1 protein conjugation (K785) was mostly exposed and accessible to SUMO1 conjugation (Fig. 2F) .
SUMOylation of EphB1 inhibits tumorigenesis
To examine the function of SUMOylated EphB1 in neuroblastoma, we first evaluated the expression of EphB1 in three neuroblastoma cell lines. As shown in Fig. 3A and B, EphB1 was widely expressed in neuroblastoma and SH-SY5Y cells had the highest EphB1 mRNA and protein expression levels among these three cell lines. Next, we overexpressed EphB1 and K785R mutant in neuroblastoma cells SH-SY5Y (Fig. 3C) . Overexpression of EphB1 significantly reduced cell proliferation, while abolishment of EphB1 SUMOylation reversed the inhibition (Fig. 3D) . Soft agar colony formation assays were performed to measure malignant transformation in cells and similar results were obtained (Fig. 3E) .
To verify the role of EphB1 SUMOylation in tumorigenesis in vivo, cells stably transfected with vector, EphB1, or K785R mutant were injected subcutaneously into nude mice. As shown in Fig. 3F , overexpression of EphB1 slightly suppressed tumor growth. In contrast, expression of K785R mutation remarkably promoted tumor growth compared with wildtype EphB1 (Fig. 3G and H) . Thus, our data revealed that SUMOylation of EphB1 was required for EphB1-mediated inhibition of tumorigenesis. 
SUMOylation of EphB1 suppresses tumorigenesis via down-regulation of PKCγ signaling
To further investigate the signaling pathway involved, we first examined the classic cancer-related pathways that have been reported to be affected by EphB1, such as Erk and Akt. However, we did not observe any difference in the level of Erk and Akt phosphorylation after overexpression of wild-type and mutant EphB1 (Fig. 4A) . Then phosphorylation of PKCγ, which was reported to regulate EphB-mediated spinal pain [23] , was detected. Interestingly, overexpression of EphB1 reduced the phosphorylation of PKCγ, whereas K785R mutation had the opposite effect (Fig. 4A) .
Given that the role of PKCγ in tumorigenesis is unclear, we stably knocked down PKCγ in cells that have been stably transfected with vector, EphB1, and K785R mutant (Fig. 4B ), respectively, and tested its effect on colony formation. As shown in Fig. 4C , knock-down of PKCγ in SH-SY5Y-Vector cells significantly inhibited colony formation, suggesting that increased tumorigenesis observed in K785R mutant transfected cells may be due to up-regulated phosphorylation of PKCγ. Indeed, knock-down of PKCγ in SH-SY5Y-EphB1 K785R cells 3 cells stably expressing vector, EphB1-WT, or K785R were mixed with medium containing 0.35% agar and 2% FBS, and seeded in 6-well plates with a bottom layer of 0.6% agar. Colonies were stained with crystal violet after culture for 14 days and the number of colonies was counted. (F) 2 × 10 6 SH-SY5Y cells overexpressing vector, EphB1-WT, or K785R were injected subcutaneously into the dorsal flank of 6-week-old male nude mice (n=4). Three weeks after injection, resulting tumors were dissected and photographed. (G) Tumor growth was measured every 4 days from 9 days after injection and tumor growth curves were plotted. (H) Tumor weight was measured and data are presented as mean ± SD.
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dramatically inhibited colony formation, while down-regulation of PKCγ had no significant effect on colony formation of SH-SY5Y-EphB1 cells. These results suggested that SUMOylation of EphB1 suppressed tumorigenesis through down-regulation of PKCγ signaling.
Phosphorylation of EphB1 inhibits its SUMOylation
Protein phosphorylation can regulate its SUMOylation both positively and negatively [24, 25] . Given that two potential PKC phosphorylation sites (S780 and S781) in EphB1 localize near the K785 SUMOylated site, we speculated if phosphorylation of the two sites could affect the SUMOylation of EphB1. We mutated S780 and S781 to phosphomimetic aspartic acid residues and performed Ni 2+ -NTA pull-down assay. Both S780D and S781D phosphomimetic mutants exhibited reduced SUMOylation (Fig. 5A) , which was confirmed by immunoprecipitation assays (Fig. 5B) . Consistently, SUMOylation of EphB1 was enhanced when S780 and S781 were mutated to non-phosphorylatable alanine residues (Fig. 5C) . To verify the specificity of Ser phosphorylation of EphB1 by PKCγ, HEK293T cells were co-transfected with HAEphB1, Ubc9, and His-SUMO1, with or without GFP-PKCγ, and then Ni 2+ -NTA pull-down Fig. 5D , overexpression of GFP-PKCγ significantly reduced the SUMOylation of EphB1.
Discussion
Here, we provide evidence that receptor tyrosine kinase EphB1 is modified by SUMOylation at lysine 785. Conjugation of SUMO1 to EphB1 suppresses the phosphorylation of its downstream signaling molecule PKCγ, and consequently inhibits tumorigenesis. In contrast, activation of PKCγ inhibits EphB1 SUMOylation (Fig. 6) .
To the best of our knowledge, this is the first study demonstrating the posttranslational modification of EphB1 by SUMO1 protein.
However, K785 mutation did not completely abolish the SUMOylation, suggesting that other lysine residues may also be SUMOylated.
The biological function of EphB1 in tumor progression is associated with cancer type. So far, no study has yet reported EphB1 in association with neuroblastoma, in which SUMOylation has been shown to be critical [26] [27] [28] . We found that overexpression of EphB1 significantly reduced malignant transformation in neuroblastoma cells, while K785R mutation reversed EphB1-mediated inhibition of tumorigenesis, suggesting that SUMOylation enhanced the role of EphB1 in tumorigenesis. Intriguingly, overexpression of EphB1-K785R promoted tumor growth in vivo compared with control, whereas in vitro experiments showed that cells transfected with EphB1-K785R grew as fast as vectortransfected cells. This may be due to the difference in detection sensitivity of the two assays. Moreover, given that EphB1 plays a role in corneal neovascularization [29] , SUMOylation of EphB1 may also play a role in tumor angiogenesis, which could only manifest in tumor growth in vivo instead of the in vitro assays we used. This deserves further study.
EphB1 suppressed phosphorylation of PKCγ, while SUMOylation deficiency abrogated this effect. Our study also demonstrated that PKCγ was oncogenic in neuroblastoma cells. Down-regulation of PKCγ inhibited tumorigenesis in EphB1-K785R stably transfected cells, but barely had any effect on EphB1-mediated tumorigenesis. Taken together, we propose that PKCγ acts as a downstream effector and participates in EphB1-regulated tumorigenesis. However, further verification will be required to further address this question. It has been reported that PKCγ promoted anchorage-independent growth of mammary epithelial cells through ERK activation [30] . Because we did not observe any change in the level of phosphorylated Erk1/2 in EphB1-overexpressing cells, other downstream signaling such as Hsp90α plasma membrane translocation [31] may be involved, rather than decreased Erk1/2 signaling.
Phosphorylation in the extension of SUMOylation motifs has been reported to either promote or inhibit SUMOylation. Our study demonstrated that phosphorylation of Ser780/781 which may be mediated by PKCγ inhibited the SUMOylation of EphB1. Previous studies showed that phosphorylation of IκBα, c-Jun, c-Fos, and p53 also inhibited their modification by SUMO [32] [33] [34] [35] . We speculated that phosphorylation of Ser780 and Ser781 might inhibit the interaction between EphB1 and the E3 SUMO-protein ligase and this requires future investigation. 
